US Puts Price Tag On False COVID-19 Claims
First Amendment No License For Health Care Providers To Make False Claims
Executive Summary
Until coronavirus public health emergency ends, FTC is authorized to order civil penalties of $43,792 per violation found in COVID-19-related advertising. Health care providers, meanwhile, advertising to treat COVID-19 might be unfamiliar with
You may also be interested in...
False Treatment Claims Still A COVID-19 Symptom: FTC Files Complaint Against California Firm
FTC files complaint alleging Precision Patient Outcomes marketed a supplement as a treatment to mitigate the effects of COVID-19 after agency let the firm know it considered the claims false advertising.
Same Old Supplement Claim Violations Prompt US Regulators’ Action Under New COVID-19 Authority
FTC files complaint against Quickwork as first action under authority granted in the COVID-19 Consumer Protection Act. The enforcement came after the firm twice ingored warnings to discontinue claims its vitamin D and zinc supplements were equal to or more effective than current vaccines.
Symptoms Change But Savings OTC Drugs Deliver For US Health Care Spending Continue Growing
Substantially more consumers in 2022 report sleep issues, allergies and skin problems than in 2018 while using quit smoking aids has dropped, according to CHPA’s latest “Value of OTC Medicines” survey. Average annual household spending on OTCs is $645.